生存期-话题@MedSci

#生存期#

350篇内容 | 2803人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378228, encodeId=a79813e82283b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=71, createdTime=2019-10-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378227, encodeId=ddb213e822704, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, objectType=article, longId=180503, objectId=941618050315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941618050315, replyNumber=0, likeNumber=79, createdTime=2019-10-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941618050315, moduleTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941618050315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378226, encodeId=69f713e8226fc, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月, objectType=article, longId=180379, objectId=ffe41803e94e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe41803e94e, replyNumber=0, likeNumber=59, createdTime=2019-10-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe41803e94e, moduleTitle=纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe41803e94e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378225, encodeId=860913e82258e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, objectType=article, longId=180287, objectId=3dc318028eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc318028eda, replyNumber=0, likeNumber=100, createdTime=2019-10-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc318028eda, moduleTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc318028eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378224, encodeId=3b2213e82241f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月, objectType=article, longId=180022, objectId=5bda180022ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bda180022ac, replyNumber=0, likeNumber=74, createdTime=2019-09-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bda180022ac, moduleTitle=JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bda180022ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378223, encodeId=c56913e8223d0, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=57, createdTime=2019-09-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378222, encodeId=77b813e822249, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期, objectType=article, longId=177733, objectId=5c4f1e77336b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f1e77336b, replyNumber=0, likeNumber=64, createdTime=2019-08-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f1e77336b, moduleTitle=Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f1e77336b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378221, encodeId=9ac713e822106, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, objectType=article, longId=177361, objectId=414c1e7361c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=414c1e7361c0, replyNumber=0, likeNumber=62, createdTime=2019-08-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=414c1e7361c0, moduleTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=414c1e7361c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378220, encodeId=39c213e822064, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=58, createdTime=2019-07-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378219, encodeId=4f4213e821973, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Zejula显著延长卵巢癌患者的无进展生存期, objectType=article, longId=175550, objectId=7f621e55508b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f621e55508b, replyNumber=0, likeNumber=69, createdTime=2019-07-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f621e55508b, moduleTitle=Zejula显著延长卵巢癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f621e55508b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JCLA：甲状旁腺切除术可降低血清完整甲状旁腺激素和钙的水平，延长老年血液透析患者严重继发性甲状旁腺功能亢进的总体生存期？, objectType=article, longId=175511, objectId=1caf1e551114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1caf1e551114, replyNumber=0, likeNumber=63, createdTime=2019-07-16, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1caf1e551114, moduleTitle=JCLA：甲状旁腺切除术可降低血清完整甲状旁腺激素和钙的水平，延长老年血液透析患者严重继发性甲状旁腺功能亢进的总体生存期？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1caf1e551114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378217, encodeId=954f13e821784, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, objectType=article, longId=175278, objectId=115d1e52785c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=115d1e52785c, replyNumber=0, likeNumber=58, createdTime=2019-07-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=115d1e52785c, moduleTitle=2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=115d1e52785c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378216, encodeId=47d513e8216de, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, objectType=article, longId=175101, objectId=26291e5101bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26291e5101bd, replyNumber=0, likeNumber=76, createdTime=2019-07-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26291e5101bd, moduleTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26291e5101bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378215, encodeId=9b2313e8215ee, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, objectType=article, longId=168704, objectId=32eb168e0473, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32eb168e0473, replyNumber=0, likeNumber=60, createdTime=2019-06-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32eb168e0473, moduleTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32eb168e0473)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378214, encodeId=a54c13e82149e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=168695, objectId=da9416869531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9416869531, replyNumber=0, likeNumber=59, createdTime=2019-06-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9416869531, moduleTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9416869531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378213, encodeId=6bcf13e8213a6, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO2019|TACE + RFA联用治疗中期（BCLC B期）肝癌改善患者生存期, objectType=article, longId=167670, objectId=f89f16e6704f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f89f16e6704f, replyNumber=0, likeNumber=70, createdTime=2019-06-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f89f16e6704f, moduleTitle=ASCO2019|TACE + RFA联用治疗中期（BCLC B期）肝癌改善患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89f16e6704f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378212, encodeId=e59113e821264, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology：扩散加权成像评价侵入性乳腺癌与无转移生存期关系的价值, objectType=article, longId=167506, objectId=0e8a16e506f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e8a16e506f1, replyNumber=0, likeNumber=70, createdTime=2019-06-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e8a16e506f1, moduleTitle=Radiology：扩散加权成像评价侵入性乳腺癌与无转移生存期关系的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e8a16e506f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378211, encodeId=be1613e821190, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=以创新为发展核心，阿斯利康专注肺癌领域，提升患者“五年生存期”, objectType=article, longId=165829, objectId=85af165829a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85af165829a6, replyNumber=0, likeNumber=75, createdTime=2019-05-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85af165829a6, moduleTitle=以创新为发展核心，阿斯利康专注肺癌领域，提升患者“五年生存期”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85af165829a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378210, encodeId=248513e821004, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=DDS：住院急性重症溃疡性结肠炎的高剂量英夫利昔单抗挽救治疗不能改善无手术生存期, objectType=article, longId=164738, objectId=fffe164e386b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fffe164e386b, replyNumber=0, likeNumber=81, createdTime=2019-04-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fffe164e386b, moduleTitle=DDS：住院急性重症溃疡性结肠炎的高剂量英夫利昔单抗挽救治疗不能改善无手术生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fffe164e386b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378209, encodeId=0e4713e8209c4, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Radiology：直肠癌晚期壁外静脉受侵MRI征象与肿瘤复发和整体生存期的关系, objectType=article, longId=162959, objectId=fbd6162959ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbd6162959ca, replyNumber=0, likeNumber=52, createdTime=2019-03-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbd6162959ca, moduleTitle=Radiology：直肠癌晚期壁外静脉受侵MRI征象与肿瘤复发和整体生存期的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbd6162959ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗

2019-10-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月

2019-10-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物

2019-10-01

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JAMA Oncology：二甲双胍抗癌实锤！临床试验证实，二甲双胍+靶向药一线治疗，可将携带EGFR突变晚期肺癌患者的生存期延长14个月

2019-09-26

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet Oncol：Nivolumab治疗与晚期非小细胞肺癌患者4年生存期

2019-08-17

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究

2019-08-11

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2019-07-27

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Zejula显著延长卵巢癌患者的无进展生存期

2019-07-17

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JCLA：甲状旁腺切除术可降低血清完整甲状旁腺激素和钙的水平，延长老年血液透析患者严重继发性甲状旁腺功能亢进的总体生存期？

2019-07-16

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019年ESMO-GI：TAS-118联合奥沙利铂显著延长晚期胃癌患者的生存期

2019-07-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期

2019-07-11

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期

2019-06-20

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期

2019-06-20

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO2019|TACE + RFA联用治疗中期（BCLC B期）肝癌改善患者生存期

2019-06-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Radiology：扩散加权成像评价侵入性乳腺癌与无转移生存期关系的价值

2019-06-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

以创新为发展核心，阿斯利康专注肺癌领域，提升患者“五年生存期”

2019-05-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

DDS：住院急性重症溃疡性结肠炎的高剂量英夫利昔单抗挽救治疗不能改善无手术生存期

2019-04-23

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Radiology：直肠癌晚期壁外静脉受侵MRI征象与肿瘤复发和整体生存期的关系

2019-03-27

科室
- - 订阅+
  - 更多科室
工具
服务